Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN Z versus XALATAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN Z versus XALATAN.
TRAVATAN Z vs XALATAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog